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Abstract
Secreted proteins of the fibroblast growth factor (FGF) family play important roles during development of various organ
systems. A detailed knowledge of their temporal and spatial expression profiles, especially of closely related FGF family
members, are essential to further identification of specific functions in distinct tissues. In the central nervous system
dopaminergic neurons of the substantia nigra and their axonal projections into the striatum progressively degenerate in
Parkinson’s disease. In contrast, FGF-2 deficient mice display increased numbers of dopaminergic neurons. In this study, we
determined the expression profiles of all 22 FGF-ligands and 10 FGF-receptor isoforms, in order to clarify, if FGF-2 deficiency
leads to compensatory up-regulation of other FGFs in the nigrostriatal system. Three tissues, ventral mesencephalon (VM),
striatum (STR) and as reference tissue spinal cord (SC) of wild-type and FGF-2 deficient mice at four developmental stages
E14.5, P0, P28, and adult were comparatively analyzed by quantitative RT-PCR. As no differences between the genotypes
were observed, a compensatory up-regulation can be excluded. Moreover, this analysis revealed that the majority of FGF-
ligands (18/22) and FGF-receptors (9/10) are expressed during normal development of the nigrostriatal system and
identified dynamic changes for some family members. By comparing relative expression level changes to SC reference
tissue, general alterations in all 3 tissues, such as increased expression of FGF-1, -2, -22, FgfR-2c, -3c and decreased expression
of FGF-13 during postnatal development were identified. Further, specific changes affecting only one tissue, such as
increased FGF-16 (STR) or decreased FGF-17 (VM) expression, or two tissues, such as decreased expression of FGF-8 (VM, STR)
and FGF-15 (SC, VM) were found. Moreover, 3 developmentally down-regulated FGFs (FGF-8b, FGF-15, FGF-17a) were
functionally characterized by plasmid-based over-expression in dissociated E11.5 VM cell cultures, however, such a
continuous exposure had no influence on the yield of dopaminergic neurons in vitro.
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Introduction
Fibroblast growth factor 2 (FGF-2) is a member of the FGF
family, which comprises small proteins of about 150–300 amino
acids length with a common conserved core domain [1]. FGF-2,
like several other secreted FGFs, is involved in distinct processes
during development of the central nervous system (CNS) and
possess neurotrophic properties for a wide range of mature
neurons [2–5]. In particular, FGF signaling regulates patterning
processes in different brain areas [6–8], proliferation of neuronal
progenitor cells and neuronal differentiation [9–12]. FGFs are
involved in formation of functional neural networks by regulating
axonal outgrowth, synapse formation and specification [13–15].
Moreover, FGF-2 has physiological relevance for dopaminergic
(DA) neurons of the nigrostriatal system [16] and FGF-2 depletion
might be related to Parkinson’s disease [17].
Based on their mode of action, the 22 mammalian FGFs have
been classified into intracrine, canonical and hormone-like FGFs
[1,18,19]. The intracrine FGFs (FGF-11/12/13/14), also known
as FGF homologous factors (FHFs, Table 1), interact with
intracellular domains of voltage gated sodium channels and are
involved in modifying the electrical excitability of neurons [20,21].
In contrast, canonical FGFs are secreted proteins, which function
in an autocrine/paracrine manner. They form ternary complexes
with heparan sulfates and extracellular domains of transmembrane
FGF-receptors (FgfRs). Formation of such complexes initiates
receptor dimerization followed by autophosphorylation of the
intracellular FgfR tyrosine kinase domain and subsequent signal
transduction. Based on phylogenetic analysis, the canonical FGFs
can be subdivided into 5 subfamilies: FGF-1/2/5, FGF-3/4/6,
FGF-8/17/18, FGF-7/10/22 and FGF-9/16/20 [1]. The re-
maining FGF ligands belong to the hormone-like (endocrine) FGFs
(FGF-15/19/21/23) thereof FGF-15 (mouse) and FGF-19 (hu-
man) are orthologous genes. Hormone-like FGFs possess a much
lower binding affinity to FgfRs and heparan sulfates compared to
canonical FGFs, which is balanced upon binding of the respective
co-receptors a-Klotho or b-Klotho [19].
Mammals possess four different FGF-receptors (FgfR-1,-2,-3,-4)
of which FgfR-1, -2 and -3 occur in different isoforms, which
originate through alternative splicing. The two major signal
transducing b and c FgfR isoforms differ in their third extracellular
Ig-like domain, which confers FGF ligand specificity. Different
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23564Table 1. Overview of FGF-ligand and FGF-receptor expression during CNS development.
qRT-PCR data ALLEN brain atlas ISH data
Gene expression level
developmental
expression Figure SC VM STR
FGF receptors
FgfR-1b low stable S1A - * - * - *
FgfR-1c high stable 1B E11-P56 * E11-P56 * P4-P56 *
FgfR-2b n.d. - low stable S1B - * - * - *
FgfR-2c moderate - high up 1D E11-P56 * E11-P28 * P14-P28 *
FgfR-3b low stable S1C - * - * - *
FgfR-3c moderate - high up 1E E11-P56 * E11-P28 * P14-P28 *
FgfR-4 low down/stable S1D n.d. n.d. n.d.
FgfRl1 moderate up/stable 1C P4, P56 P14 n.d.
a-Klotho moderate stable 1A P4, P56 - -
b-Klotho n.d. – low - - P4, P56 - -
canonical FGF ligands (grouped into subfamilies)
FGF-1/2
FGF-1 low - high up 2A P4, P56 E11-P56 P4-56
FGF-2 low - moderate up 2B n.d. n.d. n.d.
FGF-4/5/6
FGF-4 n.d. - low - - P56 n.d. n.d.
FGF-5 low stable S1E P56 n.d. n.d.
FGF-6 n.d. - - n.d. n.d. n.d.
FGF-3/7/10/22
FGF-3 low - moderate up/stable 2D P4, P56 E13-E15 n.d.
FGF-7 moderate stable S1F n.d. n.d. n.d.
FGF-10 low - moderate stable 2E n.d. n.d. n.d.
FGF-22 low - moderate up 2C - - -
FGF-8/17/18
FGF-8 n.d. - low down 2J n.d. E11, E13 n.d.
FGF-17 low - moderate down/stable 2I n.d. n.d. n.d.
FGF-18 moderate down/stable 2K P4, P56 E18-P56 P4
FGF-9/16/20
FGF-9 moderate stable S1G E11,P4,P56 E11,P4-P28 P4–P28
FGF-16 n.d. - moderate up/stable 2F n.d. n.d. n.d.
FGF-20 n.d. - low stable 2L - P4–P28 P4–P28
intracrine FGF ligands
FGF-11 moderate stable S1H P4, P56 - -
FGF-12 high stable S1I P4, P56 P4-P56 P4-P56
FGF-13 high down 2G - - -
FGF-14 moderate - high stable S1J E15,P4,P56 E15-P28 P4-P28
hormone-like FGF ligands
FGF-15 n.d. - moderate down 2H E11-E15,P4 E18 n.d.
FGF-21 n.d. - - n.d. - -
FGF-23 n.d. - - - n.d. n.d.
Quantitative RT-PCR expression levels were classified based on DCT values to Gapdh reference gene into: high (DCT,6), moderate (DCT 6–11), low (DCT.11–15) or not
detected (n.d., DCT.15). The qRT-PCR data is summarized across all tissues VM, STR and SC and all developmental stages analyzed, for detailed expression profiles see
indicated figures. Available ISH datasets of the ALLEN brain atlas were analyzed for up to 8 stages (E11.5, E13.5, E15.5, E18.5, P4, P14, P28, P56) for SC, VM and STR. The
table summarizes developmental stages with detectable expression.
*Although, FgfR-1, FgfR-2 and FgfR-3 in situ probes are homologous to FgfR c spliceforms, also b splice forms might be detected. Due to high abundance of c isoforms in
CNS most likely these isoforms have been detected by ISH.
doi:10.1371/journal.pone.0023564.t001
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receptor isoforms have been identified [22,23]. Moreover, the
complexity of FGF-FgfR interactions may be further increased by
the ability of FgfR to form heterodimers [22]. In addition, another
FGF receptor FgfR-like1 (FgfRl1 or FgfR-5) displays similarities to
extracellular ligand binding domains of the canonical FgfRs but
lacks the intracellular kinase domain. Therefore, FgfRl1 likely acts
as a decoy receptor sequestering FGFs away from canonical FgfRs
[24].
Mice deficient for individual FGF-ligands display phenotypes
ranging from mild to early embryonic lethal [1]. Likewise, rather
small phenotypic differences in the CNS of FGF-2 deficient mice
have been identified, such as reduced numbers of astrocytes in the
hindbrain and reduced numbers of specific neuron subtypes in the
cerebral cortex, hippocampal formation and spinal cord [12,
25,26]. The specification of a more severe phenotype might be
prevented by functional redundancy of co-expressed FGF-ligands.
However, no synergistic phenotypes have been observed in either
FGF-2/FGF-1 or FGF-2/FGF-5 double-deficient mice [27,28].
Our recent morphometric analysis of the nigrostriatal system
revealed, as an additional phenotype of FGF-2 deficient mice, an
increased number of substantia nigra DA neurons [29]. Based on
their binding affinity to FgfR-3c and presence in the VM, several
other FGFs have been proposed as candidates, which might
compensate for FGF-2 deficiency in the nigrostriatal system [16].
However, to date only fragmentary information on the expression
profiles of particular FGFs in the nigrostriatal system are available.
To fill this gap, we comprehensively analyzed the expression of all
22 FGF-ligands and 10 FGF-receptors (Table 1) by quantitative RT-
PCR (qRT-PCR). Particular focus was laid on the comparison of
wild-type and FGF-2 deficient mice in order to identify a possible
compensatory up-regulation of other FGF family members due to
FGF-2 deficiency. Our analysis of the nigrostriatal system, i.e.
ventral mesencephalon (VM) and striatum (STR), and as a
reference tissue spinal cord (SC), in four developmental stages
embryonic (E14.5), newborn (P0), juvenile (P28) and adult (AD)
mice, revealed that FGF-2 deficiency did not affect expression of
any other FGF-ligand or FGF-receptor. Moreover, unique insights
on the dynamic changes of the expression levels of individual FGFs
were obtained. Based on this analysis three in the VM develop-
mentally down-regulated FGF-ligands (FGF-8b, FGF-15 and FGF-
17a) were selected and their effect on DA neuron differentiation was
studied after over-expression in a well established in vitro assay.
Results
FGF-2 deficiency does not affect expression levels of
other FGF ligands and receptors
FGF-ligand and FGF-receptor expression was analyzed for 11
separate cDNA samples, comprised of 3 tissues and 4 develop-
mental stages, from both wild-type and FGF-2 deficient mice.
During the first analysis of pooled cDNA samples (see methods)
small differences between both genotypes ranging from DCT
values of 0.3 to 1.0 were identified for some genes. However,
differences did not reach statistical significance (p.0.05) after the
subsequent analysis of individual cDNA samples (n=3–7, data not
shown). While loss of FGF-2 apparently had no effect on the
expression of other FGF-ligands or receptors, at least on the
transcriptional level, our analysis identified both developmentally
regulated and stably expressed genes (see below).
The FGF-system in the developing nigrostriatal system
Given the complexity of the FGF-system, our analysis of three
CNS regions (VM, STR, SC) revealed that the majority of the
FGF-ligands (18 out of 22) and FGF-receptors (9 out of 10) are
expressed in at least two, in most cases throughout all develo-
pmental stages analyzed (Table 1). Exceptions included FGF-6,
FGF-21 and FGF-23, which were not detected in any tissue
analyzed, and FGF-4 and b-Klotho, which were absent in most
tissues except of low levels of FGF-4 (DCT=14.8) and b-Klotho
(DCT=13.5) in adult SC and P28 SC, respectively. To
discriminate between abundant and rare transcripts, the DCT
value, which is calculated by subtracting the CT value of the highly
expressed Gapdh reference gene from the CT value of the gene of
interest, was used to define four expression level categories: high
(DCT,6), moderate (DCT=6 to 11), low (DCT.11 to 15) or not
detected (DCT.15) (Table 1, Table S1). To allow a better
comparison of the expression profiles of individual genes,
expression levels were normalized to P0 SC, which was set to 1
(except for FGF-20 to P0 VM and FgfR-2b to E14.5 SC, which
were both not detected in P0 SC). The comparison of five FGF-
receptors, which displayed moderate and high expression levels,
identified stable expressed or developmentally up-regulated genes
(Fig. 1). Levels of a-Klotho and FgfR-1c remained stable during
development of SC, VM and STR (,2 fold changes, Fig. 1A,B),
whereas expression of FgfRl1 remained stable in the STR but was
temporary up-regulated at P28 in VM (3 fold) and SC (5 fold)
(Fig. 1C). Expression levels of FgfR-2c and FgfR-3c increased from
E14 to AD, most prominently after birth, in all tissues examined,
mostly in a range of 3–6 fold, except for STR FgfR-2c 2.3 fold
(Fig. 1D,E). The remaining FGF-receptor isoforms (FgfR-1b, -2b, -3b
and -4) displayed low expression levels and were mostly stable
expressed (,2 fold changes) during all developmental stages and
tissues examined, except for up-regulation of FgfR-1b in STR and
FgfR-3b in VM, and down-regulation of FgfR-4 in SC (Fig. S1A–
D).
Eleven FGF-ligands appeared in at least one tissue to be
developmentally regulated, displaying .3 fold changes between
E14 (or P0 for STR) and the AD stage (Fig. 2A–I). FGF-1, -2, -22
were up-regulated during development in all three tissues (Fig. 2A–
C), whereas expression of FGF-3, -10, -16 increased only in SC or
STR, respectively (Fig. 2D–F). FGF-13 expression decreased
during postnatal stages in all three tissues, with a 5 fold decrease
in SC and to a lesser extend in VM and STR (2.6–2.8 fold)
(Fig. 2G). Expression of FGF-15 and FGF-17 decreased in SC and
VM (Fig. 2H,I), and FGF-8 decreased in VM and STR (Fig. 2J).
FGF-18 was 3 fold down-regulated in the STR (Fig. 2K). In
addition to differences seen during development of an individual
tissue, some genes displayed differences between CNS tissue types.
Expression of FGF-1, -10, -15, -18 was highest in SC and VM
(Fig. 2A,E,H), whereas expression of FGF-3 and FGF-16 was
highest in STR (Fig. 2D,F). Strongest expression in the VM was
observed for FGF-17 and FGF-20, while FGF-8 expression was
highest in E14.5 VM and P0 STR (Fig. 2I,J,L). The remaining
FGF-ligands FGF-5, -7, -9, -11, -12, -14 displayed stable expression
levels (,2 fold changes) throughout all stages and tissues (Fig.
S1E–J). The classification of moderately and highly expressed
FGF-ligands into FGF subfamilies, revealed that all four intracrine
FGFs were highly expressed at all stages, whereas only FGF-15
among the hormone-like FGFs was moderately expressed in E14.5
SC and VM (Table 1). All canonical FGF subfamilies, with the
exception of the FGF-4/5/6 subfamily, contained members,
which were expressed at moderate to high levels (Table 1). It is
interesting to note, that individual FGF-ligands were either up-
regulated, stable or down-regulated during development, whereas
down-regulation of moderately or highly expressed FgfRs was
never observed, indicating that FGF signaling was maintained by
various FGF-ligands during development.
Nigrostriatal FGF and FgfR Expression
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23564Comparison with ALLEN Brain Atlas ISH database
The quantitative RT-PCR expression data was compared with the
publicly accessible in situ hybridization (ISH) databases of the Allen
Institute for Brain Science [30], which comprises sagittal sections of
whole mouse embryos (E11.5–E15.5) or brains (E18.5–P56) (http://
developingmouse.brain-map.org/) and SC cross sections (P4 and
P56) (http://mousespinal.brain-map.org/). High resolution bright
field ISH pictures and false colorized ‘expression mask’ pictures were
available for most FGF receptors and FGF ligands (except FGF-11, -13,
-21, -22, a-Klotho, b-Klotho in the brain database, and FGF-13, -20,
-22, -23 in the SC database, as determined on April 2011). ISH
expression levels of FGF-receptor and FGF-ligands have been summa-
rized in Table 1. In agreement with moderate to high qRT-PCR
expression levels of FgfR-1, FgfR-2 and FgfR-3 all three FgfRs have
been detected at various stages in the ALLEN ISH databases,
whereas the moderately expressed FgfRl1 was detected only in few
postnatal stages SC (P4, P56) and VM P14. Expression of FgfR-4 was
not detected by ISH, which was in agreement with the low expression
level seen by qRT-PCR. Of note, although FgfR-1, FgfR-2 and FgfR-3
ISH riboprobes were identical to the respective c isoform, they
contained also homologous regions to the respective b isoform. As the
c isoforms are more abundantly expressed in the CNS (Table 1), the
reported ISH expression pattern correspond most likely to this
isoform. Furthermore, distinction of low or absent gene expression
was difficult for some transcripts, for example brightfield pictures of
a-Klotho and b-Klotho at P56 SC, displayed both lightly stained cells
scattered throughout the gray matter, whereas false colorized
‘expression mask’ pictures were devoid of b-Klotho expressing cells
but contained few blue and green colorized cells for a-Klotho.I n
agreement to that, qRT-PCR analysis revealed moderate levels of
a-Klotho and low levels or absent expression of b-Klotho at P28 and
adult SC, respectively.
Notably, most FGFs which had been classified by qRT-PCR as
highly or moderately expressed were also detectable by ISH,
whereas low level expressed genes were not detected by ISH
(Table 1), which most likely reflects different sensitivities of both
methods. In the SC cells expressing FGF-1, -3, -9 -11, -12, -14, -18
were scattered throughout the gray matter in P4 and P56 SC. In
addition, FGFs-1, -9, -11, -18 displayed an increased expression
domain in the ventral horn of the SC. In contrast FGF-15
expression was restricted to the roof plate of the SC at E11.5–
E15.5 and to few cells close to the central canal at P4. FGF-ligands
which displayed robust ISH expression in the SC were mostly also
detected in VM and STR, however, some exceptions such as FGF-
3 were noted (Table 1). FGF-3 expression in the VM (E11.5–
E15.5) was regionally restricted, similar as seen for FGF-15 in the
VM at E18.5. This expression domain did not overlap with the
substantia nigra and most likely corresponds to the interstitial
nucleus of cajal, for which FGF-15 expression has been previously
described at E16.5 and P7 [31]. Furthermore, FGF-15 was
strongly expressed in the dorsal mesencephalon from E11.5 to
E18.5. FGF-8 was expressed at the midbrain-hindbrain border at
E11.5 and E13.5. In agreement with qRT-PCR data, FGF-18 ISH
expression in the STR decreased from P4 to P14, whereas
expression in the VM remained stable. Expression of FGF-14 was
detected throughout the brain from E15.5–P28, while FGF-12
expression was detected only in postnatal stages (P4–P28). The two
remaining intracrine FGFs (FGF-11, -13) have not been incorpo-
rated in the ALLEN brain ISH database. FGF-1 was ubiquitously
expressed in the brain from E11.5 onwards and additionally at
postnatal stages regionally more intense especially in the brain
stem. In some cases staining of P56 stage was weaker compared to
E11-P28 stages, which might reflect different ISH riboprobes used
for both ISH datasets included in the ALLEN brain atlas. For
example FGF-20 was ubiquitously expressed in the brain at P4 and
P28 stages, but was not detected at P56.
Over-expression of selected FGF-ligands
As the substantia nigra of adult FGF-2 deficient mice contains
more DA neurons compared to wild-type animals [29], we were
Figure 1. Expression profiles of the major FGF-receptors. (A,B) Expression of a-Klotho (A) and FgfR-1c (B) remained stable throughout
development of SC, VM and STR. (C) FgfRl1 was temporary up-regulated 5 fold in P28 SC and 3 fold in P28 VM, but remained stable in STR. (D,E)
Expression of FgfR-2c (D) and FgfR-3c (E) increased in all three tissues in a range of 3–6 fold from E14.5 to AD stage, except SC FgfR-2c expression
increased only 2.3 fold. Note the different scaling of the y-axis.
doi:10.1371/journal.pone.0023564.g001
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differentiation of DA progenitor cells. Therefore, E11.5 VM cells
from either wild-type or FGF-2 deficient mice were cultured for 6
days under differentiation condition in vitro. However, comparative
evaluation of tyrosine hydroxylase immunoreactivity (TH-ir),
which is the rate-limiting enzyme of DA biosynthesis, revealed
no significant difference between the genotypes by cell ELISA
technique for neuronal marker ß-Tubulin III (Fig. 3A) and TH
(Fig. 3B, Fig. 3C). While the results for the ß-Tubulin III-ir cell
ELISA measurements remained stable across the experiments, the
results for TH-ir measurement varied, probably due to subtle
differences in the age and maturation stage of DA precursor cells
of the dissected brains. In addition, counting of TH-ir cells
revealed similar numbers of DA neurons of FGF-2 deficient and
wild-type derived cells confirming the cell ELISA data (Fig. 3D).
Since FGF-8, FGF-15 and FGF-17 showed high expression levels
specifically in the embryonic VM and were down-regulated during
development, we analyzed whether a continuously high availabil-
ity of these FGFs affects TH-ir cell differentiation in vitro. There-
fore, FGF expression plasmids encoding either for FGF-2
18kDa,
FGF-8b, FGF-15 or FGF-17a were transiently transfected in
primary cultures of E11.5 VM cells, derived either from FGF-2
deficient mice or wild type mice. Cells transfected with empty-
plasmid served as control and were set to 100%. Immunocyto-
chemical detection of transfected cells by targeting the FLAG-
epitope revealed approximate 10–20% FLAG-ir cells 6 days after
Figure 2. Differentially expressed FGF-ligands. (A–F) Six FGF-ligands were up-regulated (.3 fold) during development, either in all three tissues,
such as FGF-1 (A), FGF-2 (B) and FGF-22 (C), or in single tissues, such as FGF-3 in SC (D), FGF-10 in STR (E) and FGF-16 in STR (F). (G–K) Five FGF-ligands
were down-regulated (.3 fold) during development, FGF-13 in SC (G), FGF-15 (H) and FGF-17 (I) both in SC and VM (H), FGF-8 in VM and STR (J) and
FGF-18 in STR (K). (L) Expression of FGF-20 was detected specifically in the VM at all stages. Note the different scaling of the y-axis.
doi:10.1371/journal.pone.0023564.g002
Nigrostriatal FGF and FgfR Expression
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23564transfection (Fig. 3G–J). Quantification of TH-ir cell numbers of
FGF- and empty-plasmid transfected controls revealed no
significant differences neither in wild-type nor FGF-2 deficient
VM cell preparations (Fig. 3E–F). In addition, semi quantitative
examination of three independent transfection experiments,
revealed no obvious differences between wild-type and or FGF-2
deficient cells (data not shown).
Discussion
As we previously identified a new phenotype of FGF-2 deficient
mice of increased numbers of DA neurons in the adult substantia
nigra [29], we found in the present study that a compensatory up-
regulation of other FGF-ligands or FGF-receptors, at least on the
transcript level, does not take place in the nigrostriatal system or
SC of FGF-2 deficient mice. Moreover, by using the sensitive
qRT-PCR technique most FGF-ligands (18/22) and FGF-receptors
(9/10) could be detected in VM or STR samples, although
abundance of individual genes differed strongly. Grouping of
individual FGF-ligands by FGF subfamilies revealed that all four
intracrine FGFs are abundantly expressed, whereas hormone-like
FGFs are mostly not expressed, except for expression of FGF-15 in
early stages. Particularly interesting for a potential role during DA
neuron differentiation and maintenance are secreted canonical
and hormone-like FGFs expressed in the VM. Three types of
expression profiles were discriminated during VM development,
up-regulated (FGF-1, -2, -22), down-regulated (FGF-8, -15, -17)o r
constantly expressed (FGF-5, -7, -9, -10, -16, -18, -20). The
comparison of nigrostriatal expression levels to an unrelated
region, the SC, revealed that most developmental changes applied
to all three CNS areas, indicating that the observed developmental
changes reflect general aspects of CNS development. On the other
hand, the few tissue specific distinctions at a given stage, such as
increased expression of FGF-3 and FGF-16 in the STR, FGF-17
and FGF-20 in the VM, and FGF-8 in VM and STR might point
to tissue specific roles of these genes. Indeed, FGF-20 has been
identified to be expressed in the substantia nigra and shown to
enhance the survival of DA neurons [32,33]. Further, mutations in
the FGF-20 gene locus have been associated with an increased risk
for Parkinson’s disease [34]. Early embryonic expression of FGF-8
and FGF-17 in the midbrain-hindbrain boundary has been shown
to be important for correct patterning of the brain and proper
development of the midbrain [8,35–37]. In early mouse embryos
FGF-3 expression has been detected in the midbrain and the
lateral ganglionic eminence (precursor of the striatum) of the
telencephalon, [38,39]. However, the impact of FGF-3 and FGF-
16 expression in postnatal striatum on maturation or maintenance
of DA neurons has to our knowledge not been studied.
Distinct ligand specificities of FgfRs have been identified via
mitogenic assays of transfected BaF3 cells in comparison to FGF-1,
which was used as internal control since it could activate all FGFR
isoforms [22,23]. For example, FGF-8 and -17, which were down-
Figure 3. Over-expression of FGF-2
18kDa, FGF-8b, FGF-15 or FGF-17a does not influence differentiation of DA neurons in vitro. (A–D)
Comparative evaluation of E11.5 derived VM cultures from wild-type and FGF-2 deficient mice revealed similar numbers of neurons (ß-tubulin III-ir, A)
and DA neurons (TH-ir, B), quantified either by cell-ELISA (C) or immuncytochemistry (D). (E–N) The transient over-expression of FGF-2
18kDa (G,K), FGF-
8b (H;L), FGF-15 (I,M) or FGF-17a (J,N), did not significantly increase the yield of TH-ir cells (K-N) neither in wild-type (E) nor in FGF-2 deficient VM cells
(F).
doi:10.1371/journal.pone.0023564.g003
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strongly than FgfR1c and 2c, of which FgfR2c and 3c were up-
regulated during VM development, whereas FgfR1c remained
stable. The hormone-like FGF-15, which was down-regulated as
well, displayed only weak activity for all canonical FgfRs. As the ß-
klotho co-receptor of FGF-15 [19] was not detectable in the
developing VM, an improved FGF-15/FgfRs interaction can be
excluded. The developmentally up-regulated FGF-2 activated
FgfR1c and 3c more strongly then FgfR-2c. In contrast, FGF-22
activated FgfR-2b and -1b more pronounced, which are expressed
at low levels in the VM, however weak activation of FgfR-1c,
which is expressed at high levels in the VM, could be an
alternative. Although those in vitro ligand specificities provide a
base line for comparison of different FGFs, their binding
specificities in vivo are modified by varying sulfation patterns of
heparan sulfate co-receptors present in distinct tissues and
developmental stages [40,41].
FGFs and DA neuron development
FGF-2 is a mitogen for VM neuronal precursor cells and
suppresses their differentiation into DA neurons in vitro [11].
Application of either FGF-2 or FGF-8 recombinant protein into
cell cultures of dissociated VM cells have been shown to increase
proliferation and to result, after subsequent FGF withdrawal, in
increased numbers of DA neurons compared to FGF untreated
controls [42–44]. The situation in vivo appears more complex, as
FGF-2 deficient mice display increased numbers of DA neurons
[29]. However, in this study we showed that dissociated cell
cultures derived either from E11.5 wild-type or FGF-2 deficient
mice, respectively, generate similar numbers of DA neurons in vitro,
which might indicate that differentiation regulating factors are
missing in such cultures. Secreted FGF-ligands, which are known
to influence neuron differentiation, are excellent candidates to
fulfill such function. In particular, FGF-8b expression at the
midbrain-hindbrain boundary (MHB) is required for midbrain
specification (including the substantia nigra) and has been shown
to regulate rostrally directed growth of DA axons [4,14]. Other
isoforms belonging to this FGF subfamily, such as FGF-8a, FGF-
17b and FGF-18, have been shown to possess distinct properties
for midbrain and hindbrain patterning, compared to FGF-8b
[36,37], whereas another member FGF-17a has not been analyzed
so far. FGF-15 promotes neural differentiation in the dorsal
mesencephalon and frontal cortex [9,10]. Furthermore, FGF-8,
FGF-15 and FGF-17 were expressed in E14.5 VM and down-
regulated during subsequent developmental stages as determined
by qRT-PCR. However, over-expression of FGF-8b, FGF-15,
FGF-17a or FGF-2
18kDa in vitro had no influence on the number of
mature DA neurons neither in wild-type nor in FGF-2 deficient
VM cell cultures, indicating that other factors and/or mechanism
lead to the increased DA neuron numbers seen in FGF-2 deficient
mice in vivo. One possible explanation for the multifunctionality of
FGF-2 might be attributed to different isoforms expressed in cells,
whereas for in vitro experiments only 18 kDa FGF-2 was applied.
The FGF-2 transcript contains up-stream CUG translation
initiation codons, which yields high molecular weight (HMW)
FGF-2 isoforms of 21 and 23 kDa, in addition to the AUG codon
which forms the canonical 18 kDa FGF-2 isoform. HMW FGF-2
is exclusively localized in the nucleus, while 18 kDa FGF-2 can be
found in the nucleus, cytoplasm and extracellularly released.
Moreover, distinct effects of 18 kDa FGF-2 and HMW FGF-2
isoforms have been identified, such as regulation of gene
expression, protein interaction with SMN and nuclear FgfR1/
CBP/RSK1 complexes [45–49].
FGF expression studies
Diverse techniques, such as immunohistochemistry, northern
blot, qRT-PCR, non-radioactive and radioactive ISH, which are
characterized by different assets and drawbacks in terms of
sensitivity, throughput and spatial information, have been applied
to analyze expression of FGF-ligands and FGF-receptors. Using
immunohistochemical methods FGF-1 and FGF-2 have been
detected in DA neurons of the adult substantia nigra [50]. Further,
expression during development was monitored by northern blot
and revealed constant expression levels for FGF-2 from E16.5 to
adulthood, whereas FGF-1 expression was not detected before P20
and increased further to P90 [51]. Similarly, our qRT-PCR
analysis for the developing VM revealed a rather small 3 fold up-
regulation of FGF-2 and a striking 80 fold up-regulation of FGF-1
between E14.5 and AD stage. In addition to the high detection
sensitivity, qRT-PCR technique offers the possibility to discrim-
inate between individual splice forms, such as b and c FgfR
isoforms, which differ by one alternatively spliced exon. Further,
qRT-PCR expression profiles of individual genes can be
compared, to identify similarly expressed FGF family members,
for example during development of a particular tissue, like the
developing nigrostriatal system (this study), or across diverse organ
systems at a particular developmental stage [52]. The two
independent FGF and FgfR primer sets of both studies are a
valuable tool to address similar questions in the future.
Complementary information on cellular and tissue-wide
expression patterns can be provided by ISH technique, like the
ALLEN brain atlas ISH database [30], which confirmed the
expression of highly expressed and some of the moderately
expressed genes from our qRT-PCR expression study. Differences
observed between the ALLEN brain atlas (enhanced non-
radioactive ISH) and radioactive ISH studies performed by others,
might reflect different sensitivities of both methods or design of the
ISH riboprobes. For example, in agreement with our qRT-PCR
analysis, expression patterns for all 4 intracrine FGFs have been
identified by radioactive ISH in the murine CNS at E12.5, E18.5
and adult stages [53], whereas FGF-12 was not detected at
embryonic stages in the ALLEN brain atlas. Further, expression of
FGF-20 has been confined to substantia nigra by radioactive ISH
[32], which is in agreement to low levels of FGF-20 detected by
qRT-PCR specifically in the VM, whereas the ALLEN brain atlas
reports ISH data for two distinct riboprobes, which displayed FGF-
20 either as ubiquitously expressed (P4–P28) or as not detected
(P56).
Conclusion
Whereas FGF-2 deficiency leads to increased numbers of nigral
DA neurons, expression levels of other FGFs and FgfRs were not
altered in the nigrostriatal system, which excludes a compensatory
up-regulation of the FGF-system at least on the transcriptional
level. However, it is still possible that the numerous FGFs
expressed (at normal levels) in the CNS are sufficient to prevent
the appearance of a more severe phenotype of FGF-2 deficient
mice. Future studies on compound mutant mice deficient for FGF-
2 and other FGFs, which are also expressed in the embryonic VM,
such as different members of the FGF-8/17/18 subfamily, might
uncover synergistic effects on DA neuron differentiation.
Materials and Methods
FGF-2 deficient mice and tissue processing
The FGF-2 deficient mice strain (FGF-2
tm1Zllr) was maintained
on C57BL/6 background [25]. This mutation replaces the 1
st
exon of FGF-2 with a neomycin expression cassette, thereby CUG
Nigrostriatal FGF and FgfR Expression
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isoforms were removed. Wild-type (FGF-2
+/+, wt) and FGF-2
deficient (FGF-2
2/2, ko) littermates were obtained by crossbreed-
ing of heterozygous FGF-2 mice. For time pregnancies, noon on
the day of the vaginal plug was defined as embryonic (E) day 0.5.
Genotyping was performed by PCR using improved primers,
FGF-2_GT2_wtF: 59-CTCCTGGCCTTAACCCTTTCT-39,F -
GF-2_GT2_wtR: 59-GAGGGATCAAGTCAGGCTTTG-39 and
FGF-2_GT_NeoR: 59-CCCGTGATATTGCTGAAGAGC-39.P C R
conditions were 95uC for 30 sec, 58uC for 30 sec, and 72uC for
60 sec for a total of 31 cycles, which generated PCR products
of 470 bp and 820 bp for the wild-type and mutant allele,
respectively. All experimental protocols followed German law on
animal care and were approved by Bezirksregierung Hannover,
Germany (33.9-42502-04-08/1487).
Quantitative RT-PCR
Immediately after cervical dislocation, VM, STR and SC were
dissected from of FGF-2
+/+ and FGF-2
2/2 littermates. Tissue
samples were snap frozen in liquid nitrogen and stored at 280uC.
Animals were genotyped by PCR (see above) from genomic DNA
isolated from tail tissue samples. RNA was extracted from tissue
samples of individual animals for P28 and adult stages,
respectively. For E14.5 and P0 stage, respectively, two individual
tissue samples were combined each, due to the small tissue size.
Tissue was homogenized in Trizol reagent (Invitrogen) and total
RNA was extracted as recommended by the manufacturer. To
eliminate any genomic DNA contamination a DNase (Stratagene)
digest was performed. Total RNA (1 mg) was converted into cDNA
using the iScript cDNA synthesis kit including a blend of oligo(dT)
and random hexamers (BioRad). For initial screening experiments
aliquots of individual cDNA samples isolated either from FGF-2
+/
+ or FGF-2
2/2 genotype were pooled. The pooled cDNA
contained for E14.5 and P0 stage 3 individual cDNA samples
per genotype (except 2 for P0 STR), for P28 stage 4 individual
cDNA samples per genotype and for adult stage 4 FGF-2
+/+ and 5
FGF-2
2/2 cDNA samples. In case the DDCT values of FGF-2
+/+
and FGF-2
2/2 pooled cDNA samples differed by more then 0.3
cycles, qRT-PCR was repeated with individual samples (n=3–7),
which included fresh aliquots of the original cDNAs (used also for
cDNA pooling) and if necessary samples from additional animals.
The primers for glyceraldehyde-3-phosphate dehydrogenase (Gapdh) have
been adapted from [54]. All other primer sequences were designed
with primer3 software and spanned exon-intron boundaries.
Expected size and melting points of the PCR-products are
included in Table S1. To verify the correct size of the PCR
products, qRT-PCR reactions were exemplarily separated on a
2% agarose gel (Fig. S2). The qRT-PCR was performed in 96-well
plates using the StepOnePlus instrument (Applied Biosystems) as
described previously [55]. After qRT-PCR cycling, dissociation
curves were calculated for each well and melting points were
compared to the values reported in Table S1, to ensure specificity
of the PCR product. Equal PCR efficiency of most primer pairs
(except for very low expressed FGF-20, FGF-21, FGF-23) were
validated by serial cDNA dilutions of CNS cDNA samples or
alternative tissue sources (whole E12.5 embryos, whole brain or
muscle tissue).
The data was analyzed with the StepOne
TM software version
2.1 (Applied Biosystems), with a constant threshold value of 0.2.
Fold changes in mRNA levels compared to wild type littermates
were calculated using the method and normalized to the
housekeeping gene Gapdh. Two additional housekeeping genes:
hypoxanthine guanine phosphoribosyl transferase (Hprt) and peptidylprolyl
isomerase A (Ppia) were tested, which displayed small differences in
few samples compared to Gapdh. In particular VM expression of
Hprt was reduced to 0.4 fold at E14 and increased to 1.4 fold at
P28 (Fig. S1K), whereas expression of Ppia was decreased to 0.5
fold in all three tissues at postnatal stages (Fig. S1L). Expression
levels below the detection limit, with DCT values above 15 or
which yielded no PCR product at all were assigned as not detected
(n.d.). Raw DCT values for P0 SC are included in the Table S1.
Although, we used DCT values for a crude classification into
highly, moderately or lowly expressed genes (Table 1), it has to be
noted that a more detailed comparison of the expression levels of
different genes is generally not possible, due to the fact that
conversion of mRNA transcripts into cDNA occurs with different
efficiencies for individual genes. However, the relative quantifica-
tion method used allows a accurate comparison of gene expression
levels of a given gene across different cDNA samples, such as tissue
types and stages, in relation to the SC P0 reference tissue used for
normalization. Expression levels in other stages and tissues are
depicted as fold changes compared to this reference tissue, which
was set to 1 (indicated by bold type set on the x-axis of Fig. 1,
Fig. 2, Fig. S1).
DA neuron cell culture and transfection
Dissection of mouse E11.5 VM and preparation of the
dissociated cell cultures was performed as previously described
for rat E12.5 VM cultures [44]. 30.000–40.000 cells/well were
seeded on polyornithine coated 96-well plates in attachment
medium, which contained 3% FCS (PAA), 20 ng/ml FGF-2
(Preprotech), 16 B27 (Gibco), 16 N2 (Gibco), for 1 day.
Differentiation of DA neurons was initiated by culturing for 6
days in differentiation medium, which contained 16B27, 1% FCS
and 100 mM ascorbic acid, but no N2 or FGF-2. Detailed
composition of the DMEM/F12 (Gibco) based media have been
published previously [44]. Cells used for transfection were cultured
after the first day in attachement medium for 2 additional days in
proliferation medium, which resembled the composition of
adhesion medium omitting FCS and B27 supplement. On DIV
3 transfection was performed using 0.5 ml Lipofectamine 2000
reagent (Invitrogen) and 0.2 mg plasmid DNA per well as
recommended by the manufacture. After transfection cells were
incubated for 4–6 hours in proliferation medium, followed by 6
days in differentiation medium. Expression plasmids were derived
from pCAGGS plasmid, which contained the CAG-promoter,
kindly provided by Dr. Hitoshi Niwa, RIKEN Center for
Developmental Biology, Japan [56]. Cloning of the c-terminal
3xFLAG tagged enhanced green fluorescence protein (EGFP)
expression plasmid pCAGGS-EGFP-FLAG (R412) has been
described previously [57]. The coding sequence of 18 kDa rat
FGF-2 (NM_019305.2, 533–994 bp), rat FGF-8b (corresponds to
rat FGF-8a NM_133286.1, 1–612 bp, with an 33 bp insertion
of GTAACTGTTCAGTCCTCACCTAATTTTACACAG be-
tween 69 and 70 bp), rat FGF-15 (NM_130753.1, 1–654 bp) and
rat FGF-17a (corresponds to rat FGF-17b NM_019198.1, 1–648,
without 33 bp CAGGGGGAGAATCACCCGTCTCCTAATT-
TTAAC between 69–103 bp) was amplified by PCR from rat E12
embryonic cDNA (PCR primer sequences are available upon
request). EcoRI- or MfeI-sites followed by a kozak sequence were
introduced by the forward primer and the stop-codon was
replaced by XbaI-site by the reverse primer, which allowed in
frame cloning to the 3xFLAG tag of the EcoRI/XbaI digested
pCAGGS-FLAG plasmid backbone. Thereby, the FGF expression
plasmids pCAGGS-FGF2-18kDa-FLAG (R417), pCAGGS-
FGF8b-FLAG (R421), pCAGGS-FGF15-FLAG (R423) and
pCAGGS-FGF17a-FLAG (R424) were generated.
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For fluorescence immunocytochemistry cells were fixed with 4%
PFA in PBS for 20 min at room temperature and blocked with
PBS containing 0.3% Triton X-100, 5% normal goat serum
(NGS) and 1% BSA for one hour at room temperature. The
primary antibodies rabbit anti-TH (1:500, Chemicon AB-152),
mouse anti-FLAG M2 (1:250, Sigma F-1804), mouse anti-b-
Tubulin III (1:250, Upstate Biotech, 05-559) were diluted in PBS
containing 0.3% Triton X-100, 1% NGS and 1% BSA and
incubated overnight at 4uC. The fluorochrome-conjugated secon-
dary antibodies (Invitrogen, A11001, A21429, A11008)
were applied for 1 hour. For staining of cell nuclei 49,
6-diamidino-2-phenylindole (DAPI) was applied in a dilution of
1:1000 in PBS for 5 min. Photographs were taken with AnalySIS
software (Olympus) on an inverted microscope (Olympus, IX70)
supplied with a UV lamp and Olympus ColorView 2 camera.
TH-ir cell number was quantified with ImageJ on 5 images (46
objective) or 9 images (106 objective) per well, in 3 wells per
independent experiment. Quantification of TH-ir cell number of
non-transfected E11.5 VM derived cultures was repeated twice.
Transfection experiments were performed four times, of which
TH-ir cell number was semi quantitatively examined in 3
experiments, whereas the 4
th representative experiment was
quantified (3 wells per plasmid).
Cell enzyme-linked immunosorbent assay (cell ELISA) of
primary E11.5 VM cultures was performed in 96-well plates as
previously described in 4 independent experiments with 3–7
replicates per group [58]. Minor modifications included, fixation
of the cells in methanol at 220uC for 10 min, cell permeabiliza-
tion and blocking was performed in PBS containing 10% horse
serum, 1% NGS and 0.3% Triton X-100. The primary
monoclonal antibodies, mouse anti-TH (1:200, Chemicon, MAB
5280), mouse anti-ß-Tubulin III (1:140, Upstate Biotech, 05-559)
were applied in PBS containing 1% NGS and 0.3% Triton X-100
overnight at 4uC. Bound primary antibodies were detected by
peroxidase-based avidin-biotin complex (Elite ABC kit, Vectastain)
and 2,29-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS,
Vectastain) was used as peroxidase substrate. The relative
absorbance was measured at 405 nm with microplate reader
ELX800 (Bio-Tek Instruments, Inc). Data was corrected for
unspecific staining in control wells omitting the first antibody.
Statistical analysis
The qRT-PCR data are expressed as means 6 SD. Statistically
significance of the individual cDNA samples between genotypes
were determined with unpaired Student’s t-test. The in vitro data
are expressed as means 6 SEM. TH-ir cell numbers of the
differently transfected groups were tested by Kruskal-Wallis-test
(including Dunns post hoc test) using GraphPad Prism 4 software.
P-values below 0.05 were considered as statistically significant.
Supporting Information
Figure S1 Low expressed FgfR-receptors, stable ex-
pressed FGF-ligands and additional control genes. (A–
D) Expression of the low expressed FgfR-1b (A), FgfR-2b (B), FgfR-
3b (C) and FgfR-4 (D) remained stable (,2 fold changes)
throughout development of most tissues analyzed, except for 3
fold increased FgfR-1b in STR (A), 3 fold increased FgfR-3b in VM
(C) and temporary decreased expression of FgfR-4 in all 3 tissues at
P28 (D). (E–J) Six FGF-ligands FGF-5 (E), FGF-7 (F), FGF-9 (G),
FGF-11 (H), FGF-12 (I), FGF-14 (J) remained stable expressed
throughout all stages and tissues analyzed. (K,L) Two additional
control genes Hprt (K) and Ppia (L) showed minor variation
(between 0.3 to 1.4 fold changes) compared to Gapdh used for
normalization. Expression of Ppia was consistently 2 fold decreased
in stages P28 and AD in all three tissues. Note the different scaling
of the y-axis.
(TIF)
Figure S2 PCR product gel analysis. After qRT-PCR
cycling, PCR reactions were separated on a 2% agarose gel
together with a 100 bp size marker (100 bp–1 kb in 100 bp steps).
All primer pairs produced single PCR-products of the expected
size (compare Table S1).
(TIF)
Table S1 FGF and FgfR primer sequences. Characteristic
parameters of qPCR-products (length and melting point) are
summarized in the 3
rd column. Raw DCT values obtained from
the reference tissue (P0 SC or exceptions AD SC, P0 VM, E14 SC,
P28 SC) are indicated in the 4
th column. Abbreviations: aFGF,
acidic FGF; bFGF, basic FGF; CT, threshold cycle; FHF,
fibroblast growth factor homologous factor; SC, spinal cord;
STR, striatum; VM, ventral mesencephalon.
(DOC)
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